References

1. Jorm AF, Patten SB, Brugha TS, Mojtabai R. Has increased provision of treatment reduced the prevalence of common mental disorders? review of the evidence from four countries. World Psychiatry. 2017 FEB;16:90-9.

2. Ormel J, Hollon SD, Kessler RC, Cuijpers P, Monroe SM. More treatment but no less depression: The treatment-prevalence paradox. Clin Psychol Rev. 2022;91:102111.

3. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med. 2007;357:673-81.

4. Collaborators G. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017. . 2018.

5. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al. Global variation in the prevalence and incidence of major depressive disorder: A systematic review of the epidemiological literature. Psychol Med. 2013 MAR;43:471-81.

6. Skinner A, Occhipinti J, Song YJC, Hickie IB. Population mental health improves with increasing access to treatment: Evidence from a dynamic modelling analysis. BMC Psychiatry. 2022;22:1-11.

7. Ezzati, M, et al. Contributions of risk factors and medical care to cardiovascular mortality trends. Nat. Rev. Cardiol. 2015; 12:508-530.

8. Schomerus G, Schwahn C, Holzinger A, Corrigan PW, Grabe HJ, Carta MG, et al. Evolution of public attitudes about mental illness: A systematic review and meta‐analysis. Acta Psychiatr Scand. 2012;125:440-52.

9. Nuijen J, Bon-Marten Mv, Graaf Rd, Have Mt, Poel A, Beurs Dd, et al. Zicht op depressie: De aandoening, preventie en zorg. themarapportage van de staat van volksgezondheid en zorg. . 2018.

10. Haro JM, rbabzadeh-Bouchez S, Brugha TS, de Girolamo G, Guyer ME, Jin R, et al. Concordance of the composite international diagnostic interview version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO world mental health surveys. Int J Methods Psychiatr Res. 2006 12;15:167-80.

11. Haslam N. Concept creep: Psychology's expanding concepts of harm and pathology. Psychological Inquiry. 2016 JAN 2;27:1-17.

12. Roberts BW, Luo J, Briley DA, Chow PI, Su R, Hill PL. A systematic review of personality trait change through intervention. Psychol Bull. 2017 FEB;143:117-U122.

13. Jeronimus BF, Ormel J, Aleman A, Penninx BWJH, Riese H. Negative and positive life events are associated with small but lasting change in neuroticism. Psychol Med. 2013 11;43:2403-15.

14. Malouff JM, Thorsteinsson EB, Schutte NS. The relationship between the five-factor model of personality and symptoms of clinical disorders: A meta-analysis. J Psychopathol Behav Assess. 2005 06;27:101-14.

15. Jeronimus BF, Kotov R, Riese H, Ormel J. Neuroticism's prospective association with mental disorders halves after adjustment for baseline symptoms and psychiatric history, but the adjusted association hardly decays with time: A meta-analysis on 59 longitudinal/prospective studies with 443 313 participants. Psychol Med. 2016 Oct;46:2883-906.

16. Trzesniewski KH, Donnellan MB. Rethinking "generation me": A study of cohort effects from 1976-2006. Perspectives on Psychological Science. 2010 JAN 2010;5:58-75.

17. Mroczek D, Spiro A. Modeling intraindividual change in personality traits: Findings from the normative aging study. J Gerontol B-Psychol. 2003 MAY;58:P153-65.

18. Terracciano A, McCrae RR, Costa PT,Jr. Intra-individual change in personality stability and age. Journal of Research in Personality. 2010 FEB 2010;44:31-7.

19. Cuijpers P, Karyotaki E, Reijnders M, Ebert DD. Was eysenck right after all? A reassessment of the effects of psychotherapy for adult depression. Epidemiology and psychiatric sciences. 2019 2019-Feb;28:21-30.

20. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet. 2018 APR 7;391:1357-66.

21. Huhn M, Tardy M, Spineli LM, Kissling W, Foerstl H, Pitschel-Walz G, et al. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: A systematic overview of meta-analyses. JAMA psychiatry. 2014;71:706-15.

22. Leichsenring F, Steinert C, Rabung S, Ioannidis JP. The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: An umbrella review and meta‐analytic evaluation of recent meta‐analyses. World Psychiatry. 2022;21:133-45.

23. Cuijpers P. The challenges of improving treatments for depression. Jama-Journal of the American Medical Association. 2018 DEC 25 2018;320:2529-30.

24. Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JA, Hofmann SG. Cognitive behavioral therapy for anxiety and related disorders: A meta‐analysis of randomized placebo‐controlled trials. Depress Anxiety. 2018;35:502-14.

25. Pigott HE, Leventhal AM, Alter GS, Boren JJ. Efficacy and effectiveness of antidepressants: Current status of research. Psychother Psychosom. 2010;79:267-79.

26. Furukawa TA, Shinohara K, Sahker E, Karyotaki E, Miguel C, Ciharova M, et al. Initial treatment choices to achieve sustained response in major depression: A systematic review and network meta-analysis. World Psychiatry. 2021 OCT 2021;20:387-96.

27. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR\*D report. Am J Psychiatry. 2006 11;163:1905-17.

28. Cuijpers P, Karyotaki E, Ciharova M, Miguel C, Noma H, Furukawa TA. The effects of psychotherapies for depression on response, remission, reliable change, and deterioration: A meta‐analysis. Acta Psychiatr Scand. 2021.

29. Bockting CL, Hollon SD, Jarrett RB, Kuyken W, Dobson K. A lifetime approach to major depressive disorder: The contributions of psychological interventions in preventing relapse and recurrence. Clin Psychol Rev. 2015 NOV 2015;41:16-26.

30. Sim K, Lau WK, Sim J, Sum MY, Baldessarini RJ. Prevention of relapse and recurrence in adults with major depressive disorder: Systematic review and meta-analyses of controlled trials. International Journal of Neuropsychopharmacology. 2016 FEB 2016;19.

31. Zimmerman M, Posternak MA, Ruggero CJ. Impact of study design on the results of continuation studies of antidepressants. J Clin Psychopharmacol. 2007 APR;27:177-81.

32. Biesheuvel-Leliefeld KEM, Kok GD, Bockting CLH, Cuijpers P, Hollon SD, van Marwijk HWJ, et al. Effectiveness of psychological interventions in preventing recurrence of depressive disorder: Meta-analysis and meta-regression. J Affect Disord. 2015 MAR 15;174:400-10.

33. van der Lem R, van der Wee NJA, van Veen T, Zitman FG. Efficacy versus effectiveness: A direct comparison of the outcome of treatment for mild to moderate depression in randomized controlled trials and daily practice. Psychother Psychosom. 2012;81:226-34.

34. Wang PS, Gruber MJ, Powers RE, Schoenbaum M, Speier AH, Wells KB, et al. Mental health service use among hurricane katrina survivors in the eight months after the disaster. Psychiatr Serv. 2007 Nov;58:1403-11.

35. Alonso J, Lepine JP. Overview of key data from the european study of the epidemiology of mental disorders (ESEMeD). J Clin Psychiatry. 2007;68:3-9.

36. Smolders M, Laurant M, Verhaak P, Prins M, van Marwijk H, Penninx B, et al. Adherence to evidence-based guidelines for depression and anxiety disorders is associated with recording of the diagnosis. Gen Hosp Psychiatry. 2009 SEP-OCT;31:460-9.

37. Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, et al. Clinical results for patients with major depressive disorder in the texas medication algorithm project. Arch Gen Psychiatry. 2004 07;61:669-80.

38. Monroe SM, Anderson SF, Harkness KL. Life stress and major depression: The mysteries of recurrences. Psychol Rev. 2019.

39. Ormel J, Oldehinkel AJ, Brilman EI, van den Brink W. Outcome of depression and anxiety in primary care: A three-wave 3 ½-year study of pschopathology and disability. Arch Gen Psychiatry. 1993;50:759-66.

40. Lee AS. Better outcomes for depressive disorders? Psychol Med. 2003;33:769-74.

41. Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007;27:959-85.

42. Fava GA, Rafanelli C. Iatrogenic factors in psychopathology. Psychother Psychosom. 2019;88:129-40.

43. Parry GD, Crawford MJ, Duggan C. Iatrogenic harm from psychological therapies–time to move on. The British Journal of Psychiatry. 2016;208:210-2.

44. Andrews PW, Kornstein SG, Halberstadt LJ, Gardner CO, Neale MC. Blue again: Perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Frontiers in Psychology. 2011;2:159.

45. Meadows GN, Prodan A, Patten S, Shawyer F, Francis S, Enticott J, et al. Resolving the paradox of increased mental health expenditure and stable prevalence. Australian & New Zealand Journal of Psychiatry. 2019:0004867419857821.

46. Ormel J, Bosker FJ, Hollon SD, Ruhe HG. Can loss of agency and oppositional perturbation associated with antidepressant monotherapy and low-fidelity psychological treatment dilute the benefits of guideline-consistent depression treatment at the population level? European Psychiatry. 2020 2020;63:e89.

47. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose Reduction/Discontinuation or maintenance treatment strategy long-term follow-up of a 2-year randomized clinical trial. Jama Psychiatry. 2013 SEP 2013;70:913-20.

48. De Vries Y, Roest A, de Jonge P, Cuijpers P, Munafò M, Bastiaansen J. The cumulative effect of reporting and citation biases on the apparent efficacy of treatments: The case of depression. Psychol Med. 2018;48:2453-5.

49. Ormel J, Cuijpers P, Jorm A, Schoevers R. What is needed to eradicate the depression epidemic, and why. Mental Health and Prevention. 2020;17:in press.

50. Jacka FN, Reavley NJ, Jorm AF, Toumbourou JW, Lewis AJ, Berk M. Prevention of common mental disorders: What can we learn from those who have gone before and where do we go next? Aust N Z J Psychiatry. 2013 OCT;47:920-9.

51. National Academies of Sciences, Engineering, and Medicine. *Fostering healthy mental, emotional, and behavioral development in children and youth: A national agenda*. . Washington, DC: The National Academies Press; 2019.

52. Ormel J, VonKorff M. Reducing common mental disorder prevalence in populations. Jama Psychiatry. 2021 APR 2021;78:359-60.

53. Eaton WW, Kramer M, Anthony JC, Dryman A, Shapiro S, Locke BZ. The incidence of specific dis dsm-iii mental-disorders - data from the nimh epidemiologic catchment-area program. Acta Psychiatr Scand. 1989 FEB 1989;79:163-78.

54. Newman SC, Bland RC. Incidence of mental disorders in edmonton: Estimates of rates and methodological issues. J Psychiatr Res. 1998 SEP-OCT 1998;32:273-82.

55. Bijl RV, de Graaf R, Ravelli A, Smit F, Vollebergh WA. Gender and age-specific first incidence of DSM-III-R psychiatric disorders in the general population. results from the netherlands mental health survey and incidence study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol. 2002 08;37:372-9.

56. Lehtinen V, Sohlman B, Nummelin T, Salomaa M, Ayuso-Mateos JL, Dowrick C. The estimated incidence of depressive disorder and its determinants in the finnish ODIN sample. Soc Psychiatry Psychiatr Epidemiol. 2005 OCT 2005;40:778-84.

57. Grant BF, Goldstein RB, Chou SP, Huang B, Stinson FS, Dawson DA, et al. Sociodemographic and psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety disorders: Results from the wave 2 national epidemiologic survey on alcohol and related conditions. Mol Psychiatry. 2009 NOV 2009;14:1051-66.

58. de Graaf R, ten Have M, Tuithof M, van Dorsselaer S. First-incidence of DSM-IV mood, anxiety and substance use disorders and its determinants: Results from the netherlands mental health survey and incidence study-2. J Affect Disord. 2013 JUL 2013;149:100-7.